Impact of drug adherence on blood pressure response to alcohol-mediated renal denervation

References

• Centers for Disease Control and Prevention. Vital signs: awareness and treatment of uncontrolled hypertension among adults – United States, 2003–2010. MMWR Morb Mortal Wkly Rep. 2012;61:109–709.
   Google Scholar
• GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1923–1994.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard F, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–1357.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
   PubMed Web of Science ®Google Scholar
• DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289(3):R633–R641.
   PubMed Web of Science ®Google Scholar
• Böhm M, Linz D, Ukena C, et al. Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond. Circ Res. 2014;115(3):400–409.
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Schmieder RE, Bakris G, et al. International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62(22):2031–2045.
   PubMed Web of Science ®Google Scholar
• Weber MA, Kirtane A, Mauri L, et al. Renal denervation for the treatment of hypertension: making a new start, getting it right (editorial). J Clin Hypertens. 2015;17(10):743–454.
   Web of Science ®Google Scholar
• Bohm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444–1451.
   PubMed Web of Science ®Google Scholar
• Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–2345.
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Renkin J, Sievert H, et al. Alcohol-mediated renal denervation using the peregrine system infusion catheter for treatment of hypertension. JACC Cardiovasc Interv. 2020;13(4):471–484.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Mahfoud F, Mancia G, et al. European society of hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9):1733–1741.
   PubMed Web of Science ®Google Scholar
• Fischell TA, Ebner A, Gallo S, et al. Transcatheter alcohol-mediated perivascular renal denervation with the peregrine system: first-in-human experience. JACC Cardiovasc Interv. 2016;9(6):589–598.
   PubMed Web of Science ®Google Scholar
• Fischell TA, Fischell DR, Ghazarossian VE, et al. Next generation renal denervation: chemical “perivascular” renal denervation with alcohol using a novel drug infusion catheter. Cardiovasc Revasc Med. 2015;16(4):221–227.
   PubMed Web of Science ®Google Scholar
• Fischell TA, Vega F, Raju N, et al. Ethanol-mediated perivascular renal sympathetic denervation: preclinical validation of safety and efficacy in a porcine model. EuroIntervention. 2013;9(1):140–147.
   PubMed Web of Science ®Google Scholar
• Poulter NR, Borghi C, Parati G, et al. Medication adherence in hypertension. J Hypertens. 2020;38(4):579–587.
   PubMed Web of Science ®Google Scholar
• Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–774.
   PubMed Web of Science ®Google Scholar
• Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855–861.
   PubMed Web of Science ®Google Scholar
• Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. JMCP. 2006;12(3):239–245.
   PubMed Web of Science ®Google Scholar
• Parthan A, Vincze G, Morisky DE, et al. Strategies to improve adherence with medications in chronic, ‘silent’ diseases representing high cardiovascular risk. Expert Rev Pharmacoecon Outcomes Res. 2006;6(3):325–336.
   PubMedGoogle Scholar
• Berra E, Azizi M, Capron A, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68(2):297–306.
   PubMed Web of Science ®Google Scholar
• Ruzicka M, Hiremath S. Can drugs work in patients who do not take them? The problem of non-adherence in resistant hypertension. Curr Hypertens Rep. 2015;17(9):579.
   PubMed Web of Science ®Google Scholar
• Wunder C, Persu A, Lengelé J-P, et al. Adherence to antihypertensive drug treatment in patients with apparently treatment-resistant hypertension in the INSPiRED pilot study. Blood Press. 2019;28(3):168–172.
   PubMed Web of Science ®Google Scholar
• Dell’Oro R, Quarti-Trevano F, Seravalle G, et al. Sympathetic nerve traffic and arterial baroreflex function in apparent drug-resistant hypertension. Hypertension. 2019;74(4):903–909.
   PubMed Web of Science ®Google Scholar
• Persu A, Kjeldsen S, Staessen JA, et al. Renal denervation for treatment of hypertension: a second start and new challenges. Curr Hypertens Rep. 2016;18(1):6.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–2355.
   PubMed Web of Science ®Google Scholar
• Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476–2486.
   PubMed Web of Science ®Google Scholar
• Petit G, Elena Berra E, Georges CMG, et al. Impact of psychological profile on drug adherence and drug resistance in patients with apparently treatment-resistant hypertension. Blood Press. 2018;27(6):358–367.
   PubMed Web of Science ®Google Scholar
• Pappaccogli M, Di Monaco S, Georges C, et al. Predictors of blood pressure control in patients with resistant hypertension after intensive management in two expert centres: the Brussels-Torino experience. Blood Press. 2019;28(5):336–344.
   PubMed Web of Science ®Google Scholar
• Azizi M, Pereira H, Hamdidouche I, et al. Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal denervation in the renal denervation for hypertension (DENERHTN) trial. Circulation. 2016;134(12):847–857.
   PubMed Web of Science ®Google Scholar
• Ewen S, Meyer MR, Cremers B, et al. Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol. 2015;104(12):1097–1105.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Ott C, Schmid A, et al. Adherence antihypertensive medication in Treatment-Resistant hypertension undergoing renal denervation. J Am Heart Assoc. 2016;5(2):e002343.
   PubMed Web of Science ®Google Scholar
• Jacobs L, Persu A, Huang QF, et al. European network coordinating research on renal denervation. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Press. 2017;26(6):321–331.
   PubMed Web of Science ®Google Scholar
• Durand H, Hayes P, Morrissey EC, et al. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens. 2017;35(12):2346–2357.
   PubMed Web of Science ®Google Scholar
• Pandey A, Raza F, Velasco A, et al. Comparison of Morisky medication adherence scale with therapeutic drug monitoring in apparent treatment-resistant hypertension. J Am Soc Hypertension. 2015;9(6):420–426.e2.
   PubMed Web of Science ®Google Scholar
• Burnier M, Wuerzner G, Struijker-Boudier H, et al. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension. 2013;62(2):218–225.
   PubMed Web of Science ®Google Scholar